The ultimate goal of radiation oncology research is to improve clinical care. As a specialty, we tackle diverse research questions, addressing every type of cancer and encompassing cancer biology and radiation physics.

This systematic review and meta-analysis explore the relationship between major adverse cardiac events (MACE) and radiation dose to cardiac sub-structures in lung cancer patients.

This journal activity provides practitioners with the knowledge needed in the management of Hodgkins disease with incomplete response to first line therapy.

This activity is available from September 2, 2026, through 11:59 p.m. Eastern time on September 1, 2028.

The ultimate goal of radiation oncology research is to improve clinical care. As a specialty, we tackle diverse research questions, addressing every type of cancer and encompassing cancer biology and radiation physics.

This educational activity explores the role of gynecologic re-irradiation using brachytherapy (GRIB) as a salvage treatment option for patients with loco-regionally recurrent gynecologic cancers who have previously received radiation therapy.

The educational activity reviews foundational understanding of key resistance mechanisms, the strengths and weaknesses of preclinical models, and the advancements and setbacks of treatment response to radiotherapy, chemotherapy, and immunotherapy.

The ultimate goal of radiation oncology research is to improve clinical care. As a specialty, we tackle diverse research questions, addressing every type of cancer and encompassing cancer biology and radiation physics.

This activity is for Journal Reviewers that completed a review July - September 2026.

The ultimate goal of radiation oncology research is to improve clinical care. As a specialty, we tackle diverse research questions, addressing every type of cancer and encompassing cancer biology and radiation physics.

This journal activity provides practitioners with the knowledge needed to identify major prognostic factors and the role of RT in locally advanced endometrial cancer, emphasizing multimodality therapy and molecular risk stratification in and highlighting the growing role of immunotherapy and prec